Overview

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Status:
COMPLETED

Trial end date:
2024-05-02

Target enrollment:

Participant gender:

Summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

dostarlimab